Xilio announces Q4 net income $10.4M, cash $137.5M, runway through 2027

Xilio Therapeutics, Inc.

Net income of $10.4M in Q4 2025 vs net loss of $13.1M in Q4 2024; full year net loss narrowed to $35.0M from $58.2M.
Cash and cash equivalents $137.5M at Dec 31, 2025, up from $55.3M end of 2024; cash runway extended through end of 2027.
XTX501 (bispecific PD-1/masked IL-2) on track for IND submission mid-2026 and Phase 1 start H2 2026; initial data expected H2 2027.
Advancing masked T cell engagers: CLDN18.2 program preclinical data at AACR April 2026; PSMA/STEAP1 candidate nomination Q2 2026.
Recent capital raises: $35.8M from Series B warrant exercises (Jan 2026) and $40.0M follow-on offering (Feb 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.